Granulocyte Macrophage Colony Stimulating Factor Market – Global Industry Analysis and Forecast (2024-2030)

Granulocyte Macrophage Colony Stimulating Factor Market was valued at USD 1.83 Bn in 2023 and the market size is expected to grow at a CAGR of 10.7 % through the forecast period.

Granulocyte Macrophage Colony Stimulating Factor Market Overview:

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a naturally occurring cytokine that is involved in the normal maturation and functioning of alveolar macrophages, cells involved in host defense to infection, and inflammation. The pharmaceutical analogues of naturally occurring GM-CSF are called sargramostim and molgramostim. The GM-CSF stimulates stem cells to produce granulocytes (neutrophils, eosinophils, and basophils) and monocytes.Granulocyte Macrophage Colony Stimulating Factor MarketTo know about the Research Methodology :- Request Free Sample Report Monocytes exit the circulation and migrate into tissue, whereupon they mature into macrophages and dendritic cells. It is part of the immune/inflammatory cascade, by which activation of a small number of macrophages can rapidly lead to an increase in their numbers, a process crucial for fighting infection. GM-CSF also plays a role in embryonic development by functioning as an embryokine produced by reproductive tract. The report explores the Global Granulocyte Macrophage Colony Stimulating Factor Market segments (Route of Administration, Application, End User and Region). Data has been provided by market participants, and regions (North America, Asia Pacific, Europe, Middle East & Africa, and South America). The MMR market report provides a thorough analysis of the rapid advances that are currently taking place across all industry sectors. Facts and figures, illustrations, and presentations are used to provide key data analysis for the historical period from 2018 to 2023. The report investigates the Global Granulocyte Macrophage Colony Stimulating Factor Market drivers, limitations, prospects, and barriers. This MMR report includes investor recommendations based on a thorough examination of the Global Granulocyte Macrophage Colony Stimulating Factor Market contemporary competitive scenario

Granulocyte Macrophage Colony Stimulating Factor Market Dynamics:

The competitive landscape section in the granulocyte macrophage colony stimulating factor market offers a deep dive into the profiles of the leading companies operating in the global market landscape. It offers captivating insights on the key developments, differential strategies, and other crucial aspects about the key players having a stronghold in the granulocyte macrophage colony stimulating factor market. Drivers: The increasing demand for prophylaxis granulocyte colony-stimulating factor leads to the growth of the G-CSF market. The prophylaxis with G-CSF decreases the occurrence of febrile neutropenia (FN) and allowing patients to receive and stay on myelosuppressive chemotherapy. The current use of G-CSF prophylaxis offers significant benefits including reducing incidents of febrile neutropenia by 3.3 million and cases of chemotherapy reduced dosage intensity by less than 85%, over the next 10 years. Therefore, the increasing demand for prophylaxis granulocyte colony-stimulating factor (G-CSF) is expected to drive the growth of the G-CSF market. Restrains: The high cost is the main factor which leads to the limitation of the growth of GM-CSF market. The Improved chemotherapy administration is responsible for the rise in instant medical expenses in breast cancer patients receiving primary prophylactic (PP) G-CSF. According to a study conducted by the American Journal of Managed Care, PPG-CSF administration in the first chemotherapy class was associated with a 57 % increase in total Medicare costs, despite a fall in medical costs for neutropenia. Around 42% population can be credited to the rise in the cost of chemotherapy. Therefore, the high cost is expected to obstruct the growth of the G-CSF (Granulocyte Colony Stimulating Factors) market. Challenges: The strong research and development activities will witness to the growth of the GM-CSF market. The increasing success rates in clinical trials leads to these research and development activities. Research and development are being carried out by market leaders in the Granulocyte Colony Stimulating Factors market as they continuously strive to make breakthroughs in the market in the form of new and effective drugs. Through the strategic collaborations companies in the Granulocyte Macrophage Colony Stimulating Factor are increasing their product innovation. While companies have long collaborated with each other as well as with academic and research institutions in this market by way of partnerships, in or out-licensing deals, this trend has been increasing over recent years.

Granulocyte Macrophage Colony Stimulating Factor Market Segment Analysis:

Based on application, The segment kidney cancer is dominating with the highest CAGR xx% during the forecast period. The Granulocyte-Macrophage Colony Stimulating Factor in Kidney Cancer is use to help for improving the patient's overall prognosis by stimulating the production of white blood cells. It can also help to reduce tumour size and improve response rates to chemotherapy. The use of the Granulocyte-Macrophage Colony Stimulating Factor in the Solid Tumour is to increase the number of white blood cells and improve their function. The goal is to help the patient's body fight for cancer or infection. G-MCSF may also be used to improve the quality of life for patients with advanced cancer who have a poor prognosis. Whereas, Granulocyte-Macrophage Colony-Stimulating Factor is used in lung disease to stimulate the growth of granulocytes and macrophages. It also helps in repairing tissue damage caused by infection or inflammation. Additionally, it enhances the body's immune system to fight against infection and disease.

Granulocyte Macrophage Colony Stimulating Factor Market Regional Insights:

The North America region is expected to witness significant growth at a CAGR of xx% through the forecast period because of the growing inventions in cancer research, access to cancer treatment and clinical practice in the USA. As per the National Cancer Institute (NCI), approximately 1,735,350 novel cases of cancer were diagnosed in the US. This led to the growth of GM-CSF market in the North American region. Europe holds the second-largest share in the GM-CSF market and is expected to grow at a CAGR of xx% during the forecast year. This is due to the growing use of bone and blood marrow transplantation to treat blood diseases. However, Middle East & Africa holds the least market share because of the presence of poor health spending, low income and economically diverse nations. The objective of the report is to present a comprehensive analysis of the Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The reports also help in understanding the Market dynamic, structure by analyzing the market segments and projecting the Market size. Clear representation of competitive analysis of key players by Vehicle type, price, financial position, product portfolio, growth strategies, and regional presence in the Market make the report investor’s guide.

Granulocyte Macrophage Colony Stimulating Factor Market Scope: Inquire before buying

Granulocyte Macrophage Colony Stimulating Factor Market
Report Coverage Details
Base Year: 2023 Forecast Period: 2024-2030
Historical Data: 2018 to 2023 Market Size in 2023: USD 1.83 Bn.
Forecast Period 2024 to 2030 CAGR: 10.7% Market Size in 2030: USD 3.74 Bn.
Segments Covered: by Route of Administration Subcutaneous Bolus Intravenous Infusion
by Application Solid Tumor Lymphoma Kidney Cancer Lung Disease Others
by End User Hospitals and clinics Surgical centres Diagnostic centres Research centres Others

Granulocyte Macrophage Colony Stimulating Factor Market, by Region

North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)

Granulocyte Macrophage Colony Stimulating Factor Market, Key Players

1. Aduro BioTech Inc 2. Amgen Inc 3. BriaCell Therapeutics Corp 4. Cold Genesys Inc 5. GlaxoSmithKline Plc 6. Humanigen Inc 7. Mologen AG 8. Morphotek Inc 9. Sillajen Biotherapeutics 10. Takeda Pharmaceutical Co Ltd 11. Xconomy, Inc. 12. Partner Therapeutics (PTx) 13. Sanofi-Aventis U.S. LLC 14. Novartis AG 15. Thermo Fisher Scientific 16. Merck KGaA

Frequently Asked Questions:

1] What segments are covered in the Global Granulocyte Macrophage Colony Stimulating Factor Market report? Ans. The segments covered in the Global Granulocyte Macrophage Colony Stimulating Factor Market report are based on Route of Administration, end user and Application. 2] Which region is expected to hold the highest share in the Global Granulocyte Macrophage Colony Stimulating Factor Market? Ans. North America region is expected to hold the highest share in the Global Granulocyte Macrophage Colony Stimulating Factor Market. 3] What is the market size of the Global Granulocyte Macrophage Colony Stimulating Factor Market by 2030? Ans. The market size of the Global Granulocyte Macrophage Colony Stimulating Factor Market by 2030 is expected to reach USD 3.74 Bn. 4] What is the forecast period for the Global Granulocyte Macrophage Colony Stimulating Factor Market? Ans. The forecast period for the Global Granulocyte Macrophage Colony Stimulating Factor Market is 2024-2030. 5] What was the market size of the Global Granulocyte Macrophage Colony Stimulating Factor Market in 2023? Ans. The market size of the Global Granulocyte Macrophage Colony Stimulating Factor Market in 2023 was valued at USD 1.83 Bn.
1. Global Granulocyte Macrophage Colony Stimulating Factor Market: Research Methodology 2. Global Granulocyte Macrophage Colony Stimulating Factor Market: Executive Summary 2.1. Market Overview and Definitions 2.1.1. Introduction to Global Granulocyte Macrophage Colony Stimulating Factor Market 2.2. Summary 2.2.1. Key Findings 2.2.2. Recommendations for Investors 2.2.3. Recommendations for Market Leaders 2.2.4. Recommendations for New Market Entry 3. Global Granulocyte Macrophage Colony Stimulating Factor Market: Competitive Analysis 3.1. MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2. Consolidation in the Market 3.2.1 M&A by region 3.3. Key Developments by Companies 3.4. Market Drivers 3.5. Market Restraints 3.6. Market Opportunities 3.7. Market Challenges 3.8. Market Dynamics 3.9. PORTERS Five Forces Analysis 3.10. PESTLE 3.11. Regulatory Landscape by region • North America • Europe • Asia Pacific • The Middle East and Africa • South America 3.12. COVID-19 Impact 4. Global Granulocyte Macrophage Colony Stimulating Factor Market Segmentation 4.1. Global Granulocyte Macrophage Colony Stimulating Factor Market, By Route of Administration (2023-2030) • Subcutaneous Bolus • Intravenous Infusion 4.2. Global Granulocyte Macrophage Colony Stimulating Factor Market, By Application (2023-2030) • Solid Tumour • Lymphoma • Kidney Cancer • Lung Disease • Others 4.3. Global Granulocyte Macrophage Colony Stimulating Factor Market, By End-User (2023-2030) • Hospitals and clinics • Surgical centres • Diagnostic centres • Research centres • Others 5. North America Granulocyte Macrophage Colony Stimulating Factor Market (2023-2030) 5.1. North America Granulocyte Macrophage Colony Stimulating Factor Market, By Route of Administration (2023-2030) • Subcutaneous Bolus • Intravenous Infusion 5.2. North America Granulocyte Macrophage Colony Stimulating Factor Market, By Application (2023-2030) • Hospitals and clinics • Surgical centres • Diagnostic centres • Research centres • Others 5.3. North America Granulocyte Macrophage Colony Stimulating Factor Market, By End-User (2023-2030) • Hospitals and clinics • Surgical centres • Diagnostic centres • Research centres • Others 5.4. North America Granulocyte Macrophage Colony Stimulating Factor Market, by Country (2023-2030) • United States • Canada • Mexico 6. European Granulocyte Macrophage Colony Stimulating Factor Market (2023-2030) 6.1. European Granulocyte Macrophage Colony Stimulating Factor Market, By Route of Administration (2023-2030) 6.2. European Granulocyte Macrophage Colony Stimulating Factor Market, By Application (2023-2030) 6.3. European Granulocyte Macrophage Colony Stimulating Factor Market, By End-User (2023-2030) 6.4. European Granulocyte Macrophage Colony Stimulating Factor Market, by Country (2023-2030) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 7. Asia Pacific Granulocyte Macrophage Colony Stimulating Factor Market (2023-2030) 7.1. Asia Pacific Granulocyte Macrophage Colony Stimulating Factor Market, By Route of Administration (2023-2030) 7.2. Asia Pacific Granulocyte Macrophage Colony Stimulating Factor Market, By Application (2023-2030) 7.3. Asia Pacific Granulocyte Macrophage Colony Stimulating Factor Market, By End-User (2023-2030) 7.4. Asia Pacific Granulocyte Macrophage Colony Stimulating Factor Market, by Country (2023-2030) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 8. Middle East and Africa Granulocyte Macrophage Colony Stimulating Factor Market (2023-2030) 8.1. Middle East and Africa Granulocyte Macrophage Colony Stimulating Factor Market, By Route of Administration (2023-2030) 8.2. Middle East and Africa Granulocyte Macrophage Colony Stimulating Factor Market, By Application (2023-2030) 8.3. Middle East and Africa Granulocyte Macrophage Colony Stimulating Factor Market, By End-User (2023-2030) 8.4. Middle East and Africa Granulocyte Macrophage Colony Stimulating Factor Market, by Country (2023-2030) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 9. South America Granulocyte Macrophage Colony Stimulating Factor Market (2023-2030) 9.1. South America Granulocyte Macrophage Colony Stimulating Factor Market, By Route of Administration (2023-2030) 9.2. South America Granulocyte Macrophage Colony Stimulating Factor Market, By Application (2023-2030) 9.3. South America Granulocyte Macrophage Colony Stimulating Factor Market, By End-User (2023-2030) 9.4. South America Granulocyte Macrophage Colony Stimulating Factor Market, by Country (2023-2030) • Brazil • Argentina • Rest Of South America 10. Company Profile: Key players 10.1 Aduro BioTech Inc 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2. Amgen Inc 10.3. BriaCell Therapeutics Corp 10.4. Cold Genesys Inc 10.5. GlaxoSmithKline Plc 10.6. Humanigen Inc 10.7. Mologen AG 10.8. Morphotek Inc 10.9. Sillajen Biotherapeutics 10.10. Takeda Pharmaceutical Co Ltd 10.11. Xconomy, Inc. 10.12. Partner Therapeutics (PTx) 10.13. Sanofi-Aventis U.S. LLC 10.14. Novartis AG 10.15. Thermo Fisher Scientific 10.16. Merck KGaA
  • INQUIRE BEFORE BUYING
MMRLogo
America's Fastest Growing Market Research Firm